475086-01-2
  • Air Pro475086-01-2

475086-01-2

If you are looking for a supplier or manufacturer of Selexipag(CAS: 475086-01-2), please contact us. For more than 10 years, we have been focusing on custom synthesis and large-scale manufacturing of organic compound products. We can provide high-quality compounds and good service to customers all over the world. Now, we also hope to meet your needs for Selexipag(CAS: 475086-01-2)and other compounds.

Send Inquiry

Product Description

Name

Selexipag

Synonyms

UNII-5EXC0E384L;Selexipag (JAN/USAN/INN);2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide;Selexipag [USAN:INN];2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide;NS-304;ACT-293987;MRE-304;2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide;Uptravi (brand name)

Molecular Formula

C26H32N4O4S

Molecular Weight

496.62200

CAS Number

475086-01-2

purity

≥97%

Storage conditions

Sealed in dry,2-8°C

Applications:

Selexipag (brand name Uptravi) (CAS: 475086-01-2) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.


Hot Tags: 475086-01-2,Innovative Drugs, Pharmaceutical Intermediates, API, Custom Synthesis, Chemical Custom Synthesis, Research Chemicals, Materials Science Intermediates, Catalysts and Ligands, Organometallic Catalysts, Anticancer Drugs, Leucemia, Inhibitors, Flame Retardants, Ultraviolet Absorbers, Antioxidants, Photosensitizers, PhotoInitiators

Related Category

Send Inquiry

Please feel free to give your inquiry in the form below. We will reply you within 24 hours.